Company Information
USD
1.18
- (-1.7%)
NASDAQ:ALLO, ALLOGENE THERAPEUTICS, INC.
Industry: Biotechnology
End of Day: 8 May 2025 GMT-4
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Address
210 East Grand Avenue
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Geoffrey M. Parker
CFO/Chief Accounting Officer/Executive VP
Mr. Timothy L. Moore
Chief Technology Officer/Executive VP
Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
Chairman of the Board/Co-Founder/Director
Mr. David Bonderman
Director
Mr. Joshua A. Kazam
Director
Dr. Vicki L. Sato, PhD
Director
Dr. Franz Bernard Humer, PhD
Director
Mr. Todd B. Sisitsky
Director
Dr. David D. Chang, M.D.,PhD
CEO/Co-Founder/Director/President
Dr. Owen N. Witte, M.D.
Director
Mr. John DeYoung
Director
Ms. Deborah M. Messemer
Director
Ms. Elizabeth Barrett
Director
Dr. Stephen L. Mayo, PhD
Director
Dr. Zachary Roberts, M.D.,PhD
Executive VP, Divisional
Ms. Lillian Smith
Chief Compliance Officer/General Counsel
Ownership
Institution Holdings
FMR Inc
25,241,499 (15.000%)
FMR LLC
24,917,955 (14.808%)
Pfizer Inc
22,032,040 (13.093%)
TPG GP A, LLC
18,716,306 (11.122%)
Fidelity Management & Research Company LLC
11,615,267 (6.902%)
Fidelity SelectCo, LLC
10,344,959 (6.148%)
BlackRock Inc
10,001,804 (5.944%)
Vanguard Group Inc
9,030,825 (5.367%)
JPMorgan Chase & Co
6,906,761 (4.104%)
Goldman Sachs Group Inc
6,674,428 (3.966%)
Individual Holdings
Dr. David D. Chang, M.D.,PhD
4,513,203 (2.682%)
Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
1,866,859 (1.109%)
Mr. Geoffrey M. Parker
819,400 (0.487%)
Dr. Zachary Roberts, M.D.,PhD
515,253 (0.306%)
Mr. Joshua A. Kazam
303,063 (0.211%)
Dr. Owen N. Witte, M.D.
292,832 (0.201%)
Dr. Franz Bernard Humer, PhD
266,453 (0.183%)
Mr. Timothy L. Moore
282,819 (0.168%)
Mr. Lillian Smith
140,390 (0.096%)
Dr. Vicki L. Sato, PhD
101,100 (0.069%)
Funds Holdings
Fidelity Growth Company Commingled Pool
4,134,747 (2.457%)
iShares Russell 2000 ETF
2,288,922 (1.360%)
Fidelity Growth Company Fund
2,066,903 (1.228%)
Vanguard Institutional Extnd Mkt Idx Tr
1,875,608 (1.115%)
PrimeCap Odyssey Aggressive Growth Fund
1,812,271 (1.077%)
JPMorgan Small Cap Growth Fund
1,672,662 (0.994%)
Vanguard Small Cap Index
1,397,936 (0.831%)
Fidelity Growth Company K6 Fund
1,338,901 (0.796%)
T. Rowe Price Health Sciences Fund
1,320,696 (0.785%)
Fidelity Small Cap Index Fund
938,417 (0.558%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
